BACKGROUND:
Chronic Kidney Disease (CKD) is defined as Glomerular Filteration Rate < 60ml/min/1.73m2 for a minimum of 3 months irrespective of the cause. Accelerated atherosclerosis is the main cause of morbidity and mortality in CKD patients. Visfatin is a 52KDa protein predominantly secreted by the visceral adipose tissue which has anti-inflammatory, Insulin-mimetic and antiapoptotic activities.
AIMS AND OBJECTIVE:
To estimate the levels of serum Visfatin in patients with CKD and to compare it with serum hsCRP (high sensitive C reactive protein), Ccr(Creatinine clearance) and lipid profile.
MATERIALS AND METHODS:
The study was conducted at Thanjavur Medical College Hospital. 50 patients of CKD as cases and 50 age and gender matched healthy individuals were selected as cases and controls respectively.Serum Visfatin and Serum hsCRP were estimated by Enzyme Immune Assay and Immunoturbidimetric method respectively. Serum Total Cholesterol (TC), Triglycerides (TGL), Very Low Density Lipoprotein(VLDL-C), High Density Lipoprotein (HDL-C) were
estimated by enzymatic method. Creatinine Clearance (Ccr)and Low Density Lipoprotein (LDL-C) were calculated using formula.
RESULTS:
The mean value of Visfatin in cases and controls were 27.42±8.92 and 10.62±1.57 ng/ml (t=13.11; p<0.05 significant) respectively. The level of serum visfatin is inversely correlated with Ccr (r= -0.898; p< 0.01). Serum hsCRP, TGL and VLDL-C were significantly increased and HDL-C was significantly decreased in cases when compared to controls (p < 0.05). There is no significant difference of TC between cases and controls.
CONCLUSION:
1. The present study demonstrated that serum Visfatin levels are significantly increased in patients with CKD. This increase in serum Visfatin level is progressive from the early stages to the late stages of CKD .
2. Visfatin may be considered as the novel marker of mortality predictor in CKD patients. Higher the visfatin level, higher the mortality of CKD patients
